Biodefense / Pandemic Preparedness

Where it stands

Each step compares the last four complete quarters with the two years before. A theme usually moves left to right: companies push, Congress and the White House act, the government buys, and markets respond.

1. 1. Companies pushing
   Steady

   80 companies and groups lobbied on it in Q2 2026, against 79 a year earlier.

2. 2. Congress
   Rising

   5 bills introduced and 0 became law in the last four quarters, against 2 and 0 a year before that.

3. 3. White House and agencies
   Falling

   0 proposed rules, 0 final rules and 0 presidential actions in the last four quarters, against 2 a year before that.

4. 4. Government buying
   Rising

   40 purchase plans and award notices in the last four quarters, against 30 a year before that (records start October 2023).

5. 5. Markets
   Falling

   0 insider purchases in the theme's companies in the last four quarters, against 1 a year before that. Their stocks: -42% over the same year, against +14% for the S&P 500. Among the 50 largest holdings of the funds we track, these stocks were worth $41.5M at the end of Q1 2026, against $35.5M a year earlier; the figure moves with prices and with how many funds rank them that high.

The setup

The US government is significantly bolstering its biodefense and pandemic preparedness capabilities, with the Department of Health and Human Services (HHS) leading a concentrated effort. This initiative, spanning late-stage development, procurement, and stockpiling, focuses on critical medical countermeasures like antibiotics for drug-resistant infections and nerve agent antidotes. The activity signals a sustained, multi-year commitment to national security against biological threats.

How this developed

1. Aug 18, 2025HHS awards PARAGON SYSTEMS INC a $34.9M contract for Strategic National Stockpile protective guard services.Federal contract
2. Feb 17, 2026HHS awards BOOZ ALLEN HAMILTON INC a $24.9M contract for BARDA core scientific and programmatic assistance services.Federal contract
3. Apr 6, 2026HHS awards SHIONOGI INC a $156.1M contract for late-stage development, FDA marketing authorization, procurement, and stockpile of antibiotics.Federal contract
4. Jul 28, 2026HHS awards Basilea Pharmaceutica International Ltd a $123M contract for antimicrobial development against resistant infections.Federal contract
5. Aug 19, 2026HHS awards Albert B. Sabin Vaccine Institute a $264M contract for Marburg virus vaccine R&D and procurement over 10 years.Federal contract
6. Aug 21, 2026HHS awards SHIONOGI INC a $156M contract for late-stage development and stockpiling of antibiotics for drug-resistant infections and biothreats.Federal contract
7. Sep 28, 2026HHS awards KALEO, INC. a $96M Project BioShield contract for late-stage clinical development and regulatory approval of 2-PAM autoinjectors.Federal contract
8. Oct 7, 2026HHS awards Fresenius Kabi, LLC a $24.4M contract for procurement of pharmaceuticals for the Strategic National Stockpile.Federal contract

The full story, year by year

* Year to date. Lobbying is the most companies and groups naming the theme in any one quarter. Insider buys are officer and director open-market purchases in EBS, SIGA. Fund holdings are the value of these companies among the top 50 positions of the funds whose 13F filings we track, at the latest quarter of each year. Stock returns are an equal-weight basket of the same companies with prices on file, split-adjusted, without dividends, against the S&P 500 over the same quarters.

• Lobbying before 2025 is still loading for this theme, so earlier years undercount.
• Lobbying reports for Q3 2026 are still being filed, so the comparison uses Q2 2026.

Why it matters

• HHS has committed over $700M in contracts for biodefense R&D and stockpiling since April 2026, indicating a significant and accelerating investment in medical countermeasures.
• The focus on antibiotics for drug-resistant infections (E4, E6, E8) and nerve agent antidotes (E11) highlights specific, high-priority threats the government is actively addressing.
• Multiple contracts for the Strategic National Stockpile (E2, E4, E8, E9, E13, E14) demonstrate a sustained effort to secure critical supplies and infrastructure for future emergencies.
• Long-term commitments, such as the $264M Marburg vaccine contract over 10 years (E7), signal a strategic, multi-decade approach to biodefense preparedness rather than short-term reactions.

Companies exposed to this theme

The record · 10 items, oldest first

• Aug 18, 2025Federal contractPARAGON SYSTEMS INC: STRATEGIC NATIONAL STOCKPILE PROTECTIVE GUARD SERVICES
• Feb 17, 2026Federal contractBOOZ ALLEN HAMILTON INC: BARDA CORE SCIENTIFIC & PROGRAMMATIC ASSISTANCE SERVICES
• Apr 6, 2026Federal contractSHIONOGI INC: LATE-STAGE DEVELOPMENT, FDA MARKETING AUTHORIZATION, PROCUREMENT, AND STOCKPILE OF ANTIBIOTICS FOR THE TREATMENT OF DRUG-RESISTANT SECONDARY
• Jul 28, 2026Federal contractBASILEA PHARMACEUTICA INTERNATIONAL LTD, ALLSCHWIL: $123M Department of Health and Human Services Contract
• Aug 19, 2026Federal contractALBERT B. SABIN VACCINE INSTITUTE, INC. (THE): $264M Department of Health and Human Services Contract
• Aug 21, 2026Federal contractSHIONOGI INC: $156M Department of Health and Human Services Contract
• Aug 31, 2026Federal contractFRESENIUS KABI, LLC: $112M Department of Health and Human Services Contract
• Sep 28, 2026Federal contractKALEO, INC.: THIS ACQUISITION WILL ALLOW BARDA TO INVEST PROJECT BIOSHIELD FUNDS FOR LATE-STAGE CLINICAL DEVELOPMENT, REGULATORY APPROVAL FOR 2-PAM AUTOI
• Sep 30, 2026Federal contractFRESENIUS KABI, LLC: $24.4M Department of Health and Human Services Contract
• Oct 7, 2026Federal contractFRESENIUS KABI, LLC: $24.4M Department of Health and Human Services Contract

Some keyword matches were judged unrelated to this theme and are excluded from the record above.

How this story evolved

• Oct 16, 2026, 5:14 AM ETreal50 recordslatest record Oct 7, 2026

  HHS commits over $700M to biodefense R&D and stockpiling, focusing on antibiotics and nerve agent countermeasures.

  The US government is significantly bolstering its biodefense and pandemic preparedness capabilities, with the Department of Health and Human Services (HHS) leading a concentrated effort. This initiative, spanning late-stage development, procurement, and stockpiling, focuses on critical medical countermeasures like antibiotics for drug-resistant infections and nerve agent antidotes. The activity signals a sustained, multi-year commitment to national security against biological threats.

• Oct 15, 2026, 5:15 AM ETreal55 recordslatest record Oct 7, 2026

  HHS/ASPR ramps up biodefense preparedness with focus on influenza, smallpox, and botulinum countermeasures, alongside supply chain resilience.

  The US government, primarily through the Department of Health and Human Services' Administration for Strategic Preparedness and Response (ASPR), is actively bolstering its biodefense and pandemic preparedness capabilities. This effort spans maintaining critical medical countermeasures, enhancing supply chain resilience, and investing in advanced research for biological threats. The focus is on ensuring readiness for a range of public health emergencies, from influenza to potential bioterrorism agents.

• Oct 14, 2026, 5:42 AM ETreal44 recordslatest record Oct 7, 2026

  HHS commits over $2.3B to smallpox countermeasures and antibiotic development, signaling a biodefense pivot.

  The US government is significantly ramping up its biodefense and pandemic preparedness efforts, with a clear focus on smallpox countermeasures and advanced antibiotic development. This acceleration is primarily driven by the Department of Health and Human Services (HHS), particularly through its Office of Assistant Secretary for Preparedness and Response (ASPR) and BARDA. The activity began with a foundational legislative act in late 2024, but has rapidly escalated into substantial contract awards in mid-2026.

• Oct 13, 2026, 5:15 AM ETreal45 recordslatest record Oct 7, 2026

  HHS commits over $2.3B to smallpox countermeasures and antibiotic development, signaling a biodefense pivot.

  The US government is significantly ramping up its biodefense and pandemic preparedness efforts, with a clear focus on smallpox countermeasures and advanced antibiotic development. This acceleration is primarily driven by the Department of Health and Human Services (HHS), particularly through its Office of Assistant Secretary for Preparedness and Response (ASPR) and BARDA. The activity began with a foundational legislative act in late 2024, but has rapidly escalated into substantial contract awards in mid-2026.

• Oct 12, 2026, 5:14 AM ETreal45 recordslatest record Oct 7, 2026

  HHS commits over $2.3B to smallpox countermeasures and antibiotic development, signaling a biodefense pivot.

  The US government is significantly ramping up its biodefense and pandemic preparedness efforts, with a clear focus on smallpox countermeasures and advanced antibiotic development. This acceleration is primarily driven by the Department of Health and Human Services (HHS), particularly through its Office of Assistant Secretary for Preparedness and Response (ASPR) and BARDA. The activity began with a foundational legislative act in late 2024, but has rapidly escalated into substantial contract awards in mid-2026.

• Oct 11, 2026, 5:14 AM ETreal50 recordslatest record Oct 7, 2026

  HHS/ASPR ramps up biodefense preparedness with focus on influenza, smallpox, and botulinum countermeasures, alongside supply chain resilience.

  The US government, primarily through the Department of Health and Human Services' Administration for Strategic Preparedness and Response (ASPR), is actively bolstering its biodefense and pandemic preparedness capabilities. This effort spans maintaining critical medical countermeasures, enhancing supply chain resilience, and investing in advanced research for biological threats. The focus is on ensuring readiness for a range of public health emergencies, from influenza to potential bioterrorism agents.

• Oct 10, 2026, 5:14 AM ETreal46 recordslatest record Oct 7, 2026

  HHS commits over $2.3B to smallpox countermeasures and antibiotic development, signaling a biodefense pivot.

  The US government is significantly ramping up its biodefense and pandemic preparedness efforts, with a clear focus on smallpox countermeasures and advanced antibiotic development. This acceleration is primarily driven by the Department of Health and Human Services (HHS), particularly through its Office of Assistant Secretary for Preparedness and Response (ASPR) and BARDA. The activity began with a foundational legislative act in late 2024, but has rapidly escalated into substantial contract awards in mid-2026.

• Oct 9, 2026, 5:15 AM ETreal51 recordslatest record Oct 7, 2026

  HHS/ASPR ramps up biodefense preparedness with focus on influenza, smallpox, and botulinum countermeasures, alongside supply chain resilience.

  The US government, primarily through the Department of Health and Human Services' Administration for Strategic Preparedness and Response (ASPR), is actively bolstering its biodefense and pandemic preparedness capabilities. This effort spans maintaining critical medical countermeasures, enhancing supply chain resilience, and investing in advanced research for biological threats. The focus is on ensuring readiness for a range of public health emergencies, from influenza to potential bioterrorism agents.

• Oct 8, 2026, 5:15 AM ETreal50 recordslatest record Oct 2, 2026

  HHS and DoD accelerate biodefense readiness with significant investments in vaccines, antivirals, and specialized infrastructure.

  The US government is actively bolstering its biodefense and pandemic preparedness capabilities, with a clear focus on maintaining strategic stockpiles and developing advanced medical countermeasures. This effort is primarily driven by the Department of Health and Human Services (HHS) through BARDA and ASPR, alongside targeted Department of Defense (DoD) initiatives. Recent activities indicate a sustained, multi-faceted approach to national readiness against biological threats.

• Oct 7, 2026, 5:42 AM ETreal50 recordslatest record Oct 2, 2026

  HHS and DoD accelerate biodefense readiness with major vaccine contracts and expanded strategic stockpiles.

  The US government is significantly bolstering its biodefense and pandemic preparedness capabilities, driven primarily by HHS's BARDA and ASPR, alongside DoD initiatives. This effort includes substantial investments in vaccine stockpiles, antiviral drugs, and the development of advanced medical countermeasures, indicating a sustained commitment to national readiness against biological threats.

• Oct 6, 2026, 5:15 AM ETreal74 recordslatest record Oct 5, 2026

  HHS commits $1.48B to smallpox countermeasures, while DoD seeks medical countermeasure integration for biodefense.

  The US government is actively bolstering its biodefense and pandemic preparedness capabilities, with a significant focus on medical countermeasures. This effort is spearheaded by the Department of Health and Human Services (HHS) and the Department of Defense (DoD), indicating a dual-track approach to both civilian and military readiness. Recent actions include substantial investments in smallpox vaccines and antivirals, alongside strategic planning for broader medical countermeasure development and deployment.

• Oct 5, 2026, 5:14 AM ETreal53 recordslatest record Oct 2, 2026

  HHS commits over $1.5B to smallpox countermeasures and pandemic preparedness, while DoD seeks medical countermeasure integration.

  The US government is significantly investing in biodefense and pandemic preparedness, with a strong focus on medical countermeasures. This effort is primarily driven by the Department of Health and Human Services (HHS) and the Department of Defense (DoD), with HHS awarding over $1.5 billion in contracts for smallpox vaccines and antivirals. The activity indicates a sustained, multi-agency commitment to bolstering national readiness against biological threats.